The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 21, 2026

Filed:

Jan. 20, 2023
Applicant:

Sun Yat-sen University, Guangdong, CN;

Inventors:

Sheng Yin, Guangdong, CN;

Xuelong Yan, Guangdong, CN;

Junjian Wang, Guangdong, CN;

Jialuo Huang, Guangdong, CN;

Guihua Tang, Guangdong, CN;

Assignee:

SUN YAT-SEN UNIVERSITY, Guangzhou, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 303/32 (2006.01); C07D 491/18 (2006.01); C07D 491/22 (2006.01);
U.S. Cl.
CPC ...
C07D 491/22 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 303/32 (2013.01); C07D 491/18 (2013.01);
Abstract

The invention relates to a daphnane diterpenoid resistant to a prostate cancer and a preparation method thereof. A daphnane diterpenoid compound as represented by formula (I) or formula (II) significantly inhibits the proliferation of various prostate cancer cells; the activities of some such compounds at a cellular level and an animal level are higher than that of the existing clinical targeting drug enzalutamide; and the daphnane diterpenoid compounds have strong synergistic effects when used in combination with the enzalutamide and are expected to become candidate drugs for treatment or adjuvant treatment of a castration-resistant prostate cancer.


Find Patent Forward Citations

Loading…